ClinicalTrials.gg
RecruitingNCT05451784TILS001Updated Nov 2, 2026

Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS

A Phase 1/2 interventional study of PD1+ TILs (NUMARZU-001) product infusion in Metastatic Triple-Negative Breast Carcinoma, sponsored by Fundacio Clinic Barcelona. Recruiting at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Fundacio Clinic Barcelona · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Triple Negative Breast Neoplasms with a site in Spain — 24 open to participants now, 48 under way, 10 of them phase 3. Triple Negative Breast Neoplasms · Spain.

Planned enrollment
130th of 134
20 · median 150
Started
2022
with 11 others
Phase 1/2
28 of 136
7 open now
Primary completion
2028-09
later than 31 of 47 live
Registered
106th of 136
by date

Among the 136 studies in Triple Negative Breast Neoplasms with a site in Spain, this one is the 130th largest by planned enrollment of the 134 interventional ones that give a count, is one of 12 that started in 2022, is one of 28 in phase 1/2, reaches primary completion later than 31 of the 47 other live ones, and was the 106th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

24 of the 136 studies in Triple Negative Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Triple Negative Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This is a prospective, multicenter, phase I/II, open-label, two-stage design of PD1+ TILs infusion in metastatic or advanced TNBC. TILS001 includes 3 parts. Previous to each phase inclusion, a specific ICF must be signed by the patient. Participants potentially eligible to participate in the clinical trial will be offered to sign a ICF three times prior to TILs treatment: 1) to allow for collection of archival FFPE tissue samples for determination PD1 by mRNA (Part #1), 2) prior to a fresh metastatic biopsy for selection, isolation and partial expansion of PD1+ TILs (Part #2) and 3) prior to allow for remaining study procedures and TILs therapy (Part #3, Main Consent).

Read the detailed description

This trial has been developed in TNBC, a breast cancer subtype with a particularly poor prognosis. The product used for treating participating patients will be selected PD1-positive TILs. Such TILs will be manufactured in Hospital Clinic under the name of NUMARZU-001. The procotol has been designed in three parts to better select participating patients. Molecular pre-screening has been established to select tumors with a higher probability of enrichment by PD1-positive TILs. The pre- screening consists of performing a tumor biopsy and selecting isolation and expansion of PD1- postive TILs to manufacture the final product NUMARZU-001. This part could last almost four weeks, as such patients will continue with the established treatment in the meanwhile. Finally, NUMARZU-001 will be administered if the patient is eligible for part three of the protocol.

03

Conditions studied

  • Metastatic Triple-Negative Breast Carcinoma

Keywords

  • TNBC
  • Breast Cancer
  • metastatic
  • triple negative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility criteria for Part #1 (Molecular pre-screening: Determination of PD1 by mRNA analysis from an archival FFPE tumor sample):

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Age ≥ 18 years.
  2. Estimated of ≥6 months.
  3. confirmed diagnosis of unresectable or breast cancer.
  4. Histologically confirmed diagnosis of advanced triple-negative breast cancer (based on the most recently analyzed from locally recurrent or metastatic site, local laboratory) meeting the following criteria: -negative in situ hybridization test or an immunohistochemistry (IHC) status of 0 or 1+, and ER and PgR expressions \<10% as determined locally by IHC assay as per most recent ASCO/CAP guidelines.
  5. Patients could have received a maximum of 5 lines of prior standard of care chemotherapy in the inoperable/metastatic setting.
  6. Patients must not have history of other within the past 3 years with the following exceptions: adequately treated non-melanoma skin cancer without evidence of disease at the time of enrollment; adequately treated cervical carcinoma in situ without evidence of disease at the time of enrollment; adequately treated breast ductal carcinoma in situ without evidence of disease at the time of enrollment; prostatic intraepithelial neoplasia without evidence of prostate cancer at the time of enrollment; adequately treated superficial or in-situ carcinoma of the bladder without evidence of disease at the time of enrollment.
  7. Subject likely to be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
  8. Absence of psychiatric or physiologic history, substance abuse, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  9. Patients must have an (ECOG) performance status of 0 or 1.
  10. Pregnant or breastfeeding women will NOT be eligible.
  11. Subject has known sensitivity to any of the products or components to be administered during dosing will NOT be eligible.
  12. NOT having an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is site or sponsor staff directly involved in this trial, unless prospective institutional review board (IRB)/independent ethics committee (IEC) approval (by chair or designee) is given allowing an exception to this criterion for a specific subject
  13. Patients must NOT have undergone prior hematopoietic stem cell transplantation
  14. Patients with a history or evidence of symptomatic will NOT be eligible: glomerulonephritis, vasculitis, or other symptomatic autoimmune diseases, or active autoimmune disease or syndrome that has required systemic treatment in the past 2 years (ie, with the use of disease-modifying agents, or drugs) except vitiligo or resolved childhood asthma/atopy. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  15. Absence of active bacillus tuberculosis history.
  16. Absence of a known history of (HIV). Note: No HIV testing is required.
  17. Absence of a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV RNA is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required.
  18. To be able to provide either a newly obtained tumor biopsy (preferred) or archival tumor tissue of an FFPE tumor block. The tumor tissue should be of good quality based on total and viable tumor content and must be evaluated centrally for gene expression analysis prior to enrollment in Part #2.

Eligibility criteria for Part #2 (Pre-Screening Phase: Selection, isolation and partial expansion of PD1+ TILs from a fresh tumor sample):

Participants are eligible to be included in the study only if all the previous and the following criteria apply:

  1. Patients will be eligible for Part #2 if they have a mRNA expression above the 20th percentile in the FFPE tumor sample analyzed in Part 1.
  2. At least 1 resectable target lesion
  3. Patients must NOT have clinically active cerebral metastases. Carcinomatous meningitis is not allowed regardless of clinical stability.

Eligibility criteria for Part #3 (Screening and treatment Phase: Complete expansion of PD1+TILs. Treatment of patients with PD1+ TILs infusion):

Participants are eligible to be included in the study only if all of the previous and the following criteria apply. For being included in this section, the following criteria must apply:

  1. PD1+ TILs selection in Part #1 and successful partial expansion of tumor sample in Part #2
  2. Treatment-related toxicities (except alopecia and neuropathy G2) must ≤ Grade 1 at the time of allocation according to version 5.0.
  3. All patients must have received two or more prior systemic therapies, including at least one of them for advanced disease and an ADC. A maximum of five chemotherapy-based lines are permitted in the metastatic setting. Prior treatment should be discontinued 28 days or 5 half-lives, whichever is shorter, before day 1 of NMA-LD.
  4. according to 1.1 criteria.
  5. Adequate organ function determined within 28 days prior to enrollment.
  6. Female subjects of must have a negative urine or serum pregnancy test within 72 hours prior to enrollment.
  7. For patients ≥ 60 years or patients who have a history of ischemic heart disease, chest pain, or atrial and/or ventricular arrhythmias, a cardiac stress tests must be performed showing normal , functional classification \< class 1 and if any wall movement abnormalities, they must be reversible.
  8. Left ventricular ejection fraction (LVEF) ≥ 50% at baseline as determined by either ECHO or MUGA
  9. Patients must not be currently receiving treatment with another investigational device or drug study. No other investigational procedures (of any kind) are permitted while participating in this study.
  10. Systemic steroid therapy is not permitted (patients who require replacement therapy for adrenal insufficiency may be enrolled if the steroid treatment dose does not exceed 10 mg of prednisone or equivalent).
  11. Patients with evidence of clinically significant immunosuppression will NOT be eligible.
  12. Patients with evidence of (non-infectious) pneumonitis that required steroids or current pneumonitis will NOT be eligible.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    PD1+ TILs (NUMARZU-001) product infusion

    The treatment administration is divided in NMA-LD chemotherapy(auxiliary medication), TILs product (IMP) and IL-2 (auxiliary medication).

    Drug: PD1+ TILs (NUMARZU-001) product infusion

Interventions

  • DrugPD1+ TILs (NUMARZU-001) product infusion

    Drug page: Therapeutic Tumor Infiltrating LymphocytesStudies of Therapeutic Tumor Infiltrating LymphocytesTherapeutic Tumor Infiltrating Lymphocytes pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute. Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following: * Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion. * Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist. Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction).

    Also known as: TILs

06

What researchers measure

Primary outcomes

  1. Incidence of grade 3-5 adverse event (AE)

    Incidence of grade 3-5 adverse event (AE) assessed by the NCI Common Terminology for Classification of Adverse Events (CTCAE) version 5.0, and any grade AE assessed by CTCAE that leads to treatment discontinuation and possibly related to treatment, that occur in the first 24h following PD1+ TILs infusion (prior to IL-2 treatment). * Incidence of grade 3-5 AEs assessed by the NCI CTCAE version 5.0 taking into account the whole process, which includes NMA-LD chemotherapy followed by TILs infusion and at least one dose of IL-2 treatment. * All changes in treatment administration including delays, interruptions, reductions or discontinuation and the main reason(s) for these changes.

    Time frame: 24 weeks from the administration of PD1+ TILS (NUMARZU-001 product)

  2. Overall response rate (ORR)

    Overall response rate (ORR) locally determined as the best response (defined as CR and PR) by the investigator according to RECIST 1.1 criteria from the administration of PD1+ TILS (NUMARZU-001 product); on day 0

    Time frame: 24 weeks from the administration of PD1+ TILS (NUMARZU-001 product)

Secondary outcomes

  1. Progression-Free Survival at 6 months(PFS6)

    Progression-Free Survival at 6 months(PFS6) defined as the proportion of patients alive and without progression (as determined locally by the investigator according to Response Evaluation Criteria in Solid Tumor \[RECIST\] 1.1 version) 24 weeks from the administration of PD1+ TILS (NUMARZU-001 product); on day 0

    Time frame: 24 weeks from the administration of PD1+ TILS (NUMARZU-001 product)

  2. Clinical Benefit Rate at 6 months (CBR6)

    Clinical Benefit Rate at 6 months (CBR6) from the administration of PD1+ TILS (NUMARZU-001 product); on day 0 defined as Complete response (CR), Partial response (PR) or Stable Disease (SD) for at least 6 months, as determined locally by the investigator according to RECIST 1.1 criteria.

    Time frame: 24 weeks from the administration of PD1+ TILS (NUMARZU-001 product)

  3. Duration of Response (DoR)

    Duration of Response (DoR) defined as the time from the first occurrence of a documented objective response to disease progression, as determined locally by the investigator using RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: 24 weeks from the administration of PD1+ TILS (NUMARZU-001 product)

  4. Progression-free survival (PFS)

    Progression-free survival (PFS) defined as the timefrom the administration of PD1+ TILS (NUMARZU-001 product); on day 0 to the first occurrence of disease progression, as determined locally by the investigator using RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: 24 weeks from the administration of PD1+ TILS (NUMARZU-001 product)

  5. Overall Survival (OS)

    Overall Survival (OS) defined as the time from the administration of PD1+ TILS (NUMARZU-001 product); on day 0 to death due to any cause.

    Time frame: From completion of the Response Assessment Period and up to 5 years from the last study treatment until death, loss to follow-up, or withdrawal of consent

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Sep 2028, 74 months after the start.

Of 118 phase 1/2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 79. This study's planned 74 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Nov 2025 → Sep 2028 and completion Sep 2027 → Mar 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2022
First posted
Jul 11, 2022
StartActual
Jul 20, 2022
Primary completionEst.
Sep 30, 2028was Nov 2025
CompletionEst.
Mar 30, 2032was Sep 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Hospital Clinic de Barcelona · Barcelona, Spain
Show 1 removed
  • Hospital Clinic de Barcelona · Barcelona, Spain
Nov 2, 2026
Primary completion
Nov 30, 2025→Sep 30, 2028
Nov 2, 2026
Study completion
Sep 30, 2027→Mar 30, 2032
Nov 2, 2026
Contact
Study contact changed: t•••@gruposolti.org · •••6302→i•••@gruposolti.org · •••6302; L•••@clinic.cat→none listed. See the current contact
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added, 1 site removed
    Show site
    • Hospital Clinic de Barcelona · Barcelona, Spain
    Show 1 removed
    • Hospital Clinic de Barcelona · Barcelona, Spain
    Primary completion Nov 30, 2025→Sep 30, 2028
    Study completion Sep 30, 2027→Mar 30, 2032
    Contact Study contact changed: t•••@gruposolti.org · •••6302→i•••@gruposolti.org · •••6302; L•••@clinic.cat→none listed. See the current contact
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05451784
Lead sponsor
Fundacio Clinic Barcelona
Collaborators
SOLTI Breast Cancer Research Group
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Jul 20, 2022
Primary completion
Sep 30, 2028 (estimated)
Completion
Mar 30, 2032 (estimated)
Last update
Nov 2, 2026

Study contacts

Victor Albarran
Contact
info@gruposolti.org
+ 34 933 436 302
Laura Angelats
Contact
Aleix Prat
study chair · Hospital Clinic
Laura Angelats
study chair · Hospital Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Therapeutic Tumor Infiltrating Lymphocytes

Start the discussion